Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 80 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neonatal Seizure Clear all

Conditions: Colorectal Cancer
Interventions: Fecal immunochemical test; Other
Lead sponsor: University of Chicago; Other
Eligibility: 20 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Chicago, Illinois • Ann Arbor, Michigan • New York, New York

Conditions: MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
Interventions: Glycerol Tributyrate; Drug
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Citrate Transporter Deficiency, Epilepsy, Rare Diseases, Movement Disorders, Genetic Disorder, SLC13A5 Deficiency, EIEE25, Kohlschutter-Tonz Syndrome (non-ROGDI), 17p13.1 Deletions Confined to SLC13A5 Gene, Citrate Transporter Disorder
Interventions: Not listed
Lead sponsor: TESS Research Foundation; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Developmental and Epileptic Encephalopathies, Epileptic Spasms, Genetic Epilepsy, Neonatal and Infant Epilepsy
Interventions: Ketogenic diet; Drug
Lead sponsor: Heather Olson; Other
Eligibility: 0 Days to 9 Months
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Epilepsy, Benign Neonatal
Interventions: Phenobarbital Sodium Injection; Drug
Lead sponsor: NEMA Research, Inc.; Industry
Eligibility: 34 Weeks to 44 Weeks
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Little Rock, Arkansas • Washington D.C., District of Columbia • Miami, Florida + 3 more

Conditions: Plagiocephaly, Nonsynostotic
Interventions: Serkel 3D CRO; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 4 Months to 18 Months
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Neonatal Seizure, Epilepsy, Seizures, Inflammatory Response
Interventions: Blood draw, Survey; Diagnostic Test · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 1 Day to 4 Days
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 4
States / cities: Oakland, California • San Francisco, California • Boston, Massachusetts + 1 more

Conditions: Epilepsy; Seizure, Neuromuscular Diseases, Brain Malformation, Intellectual Disability, Autism Spectrum Disorder, Hypotonia, Inborn Errors of Metabolism, Movement Disorders, Genetic Disease, Development Delay, Chromosome Abnormality, Hearing Loss, Dysmorphic Features, Skeletal Dysplasia, Congenital Abnormality, Microcephaly, Macrocephaly
Interventions: Pre-visit prep, usual care + exome seq; Behavioral · Diagnostic Test
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 0 Years and older
Enrollment: 548 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 3
States / cities: Asheville, North Carolina • Chapel Hill, North Carolina • Greenville, North Carolina

Conditions: Autosomal Dominant Hypocalcemia (ADH)
Interventions: Encaleret, Standard of Care; Drug · Dietary Supplement
Lead sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company; Industry
Eligibility: 16 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 11
States / cities: Oakland, California • Aurora, Colorado • Indianapolis, Indiana + 8 more

Conditions: Hypoxic-Ischemic Encephalopathy, Brain Injury, Neonatal Seizure
Interventions: Neurologic examination; Other
Lead sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre; Other
Eligibility: Up to 6 Hours
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 4
States / cities: Detroit, Michigan • Columbus, Ohio • Providence, Rhode Island + 1 more

Conditions: Epilepsy
Interventions: retigabine/ezogabine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 29 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Los Angeles, California • Wellington, Florida • Memphis, Tennessee + 1 more

Conditions: Tuberous Sclerosis Complex
Interventions: everolimus; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 14
States / cities: Phoenix, Arizona • Los Angeles, California • Oakland, California + 11 more

Conditions: Gaucher's Disease
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Seizures, Lennox Gastaut Syndrome
Interventions: Carisbamate; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 4 Years to 55 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 22
States / cities: Palo Alto, California • Jacksonville, Florida • Orlando, Florida + 18 more

Conditions: Lennox Gastaut Syndrome
Interventions: Clemizole HCl, Placebo; Drug
Lead sponsor: Epygenix; Industry
Eligibility: 2 Years to 55 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 22
States / cities: Little Rock, Arkansas • Orange, California • Miami, Florida + 16 more

Conditions: Headache, Tumor, Seizure Disorder, Neurofibromatoses, Hydrocephalus, Abdominal Neoplasm, Spine Deformity
Interventions: propofol, Dexmedetomidine, Glycopyrrolate, Lidocaine 1% Injectable Solution, Nitrous Oxide, Sevoflurane; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 12 Months to 60 Months
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Neonatal Seizure, Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy, Seizure Newborn
Interventions: Levetiracetam Injection, Phenobarbital Sodium Injection; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: Up to 1 Month
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: San Diego, California • Minneapolis, Minnesota

Conditions: Lennox Gastaut Syndrome
Interventions: Not listed
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: Up to 26 Years
Enrollment: 4,680 participants
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Chicago, Illinois • Ann Arbor, Michigan • St Louis, Missouri + 1 more

Conditions: Seizures
Interventions: levetiracetam; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Day to 30 Days
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Tuberous Sclerosis Complex
Interventions: Early Vigabatrin, Delayed Vigabatrin (Placebo); Drug
Lead sponsor: Martina Bebin; Other
Eligibility: 1 Day to 6 Months
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 10 more

Conditions: Tuberous Sclerosis Complex
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Day to 6 Months
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 5
States / cities: Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 2 more

Conditions: Seizures, Encephalopathy, Asphyxiated Newborn
Interventions: Not listed
Lead sponsor: Sharp HealthCare; Other
Eligibility: 1 Day and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 1
States / cities: San Diego, California

Conditions: Tuberous Sclerosis Complex, Seizures
Interventions: GWP42003-P; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 1 Year to 65 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Epilepsy
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

FITting Non-invasive Tests in Lynch Syndrome Surveillance

A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)

SLC13A5 Deficiency Natural History Study - Remote Only

Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies

Efficacy and Safety of Intravenous Phenobarbital in Neonatal Seizures

Observe the Effects of the Serkel Cranial Remolding Orthosis on Infants With Deformational Plagiocephaly

Evaluating the Role of Inflammation in Neonatal Epileptogenesis

North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2

Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1

Prospective Research in Infants With Mild Encephalopathy

Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Effects of Enzyme Replacement in Gaucher's Disease

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

Dexmedetomidine and Propofol for Pediatric MRI Sedation

A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures

Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome

Dosing of Levetiracetam (Keppra) in Neonates

Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex

Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC

Novel Epidermal Recording and Detection of Seizures

An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Herpes Virus-6 and Epilepsy